Bevacizumab biosimilar (Shanghai Kangdai)

贝伐珠单抗生物类似药（上海康岱）

Report date: 2025/12/07 20:00:07

Base Information

Drug NameBevacizumab biosimilar (Shanghai Kangdai)
Drug Alias NameRecombinant humanized anti-VEGF monoclonal antibody (Shanghai Kangdai Biotech)重组人源化抗VEGF单抗注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Kanda Bio-Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Kanda Bio-Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A